A reference desk for uneven evidence

What this site is

Boston Peptide is an independent editorial digest of four peptide research records: GHK-Cu, semaglutide, tesamorelin, and BPC-157. It uses the Boston research landscape as a frame for close reading: methods before headlines, populations before generalization, and regulatory terms used with precision.

The site is not a clinic, pharmacy, seller, trial recruiter, or product-ranking service. It does not prescribe, diagnose, broker compounds, or turn study protocols into personal instructions. Its job is narrower and useful: make a complex literature set readable while preserving the boundaries that give the evidence meaning.

The compounds were selected because they expose important differences hidden by the phrase “research peptide.” One is a copper-binding topical research subject, one is a mature GLP-1 medicine, one is a GHRH analogue with a narrow approval, and one is an unapproved compound with predominantly preclinical evidence. Reading them together teaches research literacy better than treating the category as uniform.

How the evidence is edited

Every technical dossier begins with a plain-language orientation. Later sections add molecular detail, study findings, safety, anecdotal reports, and regulatory context. Bracketed citations connect claims to the shared reference list. Quantitative findings remain attached to those citations and to the models or populations that produced them.

The evidence hierarchy shapes the verbs. A randomized human trial can establish a result within its protocol. A review can synthesize a body of work but inherits the quality of that work. Cell and animal models can clarify mechanisms and generate hypotheses. They cannot prove a human benefit. A two-person pilot can record an observation but cannot define a safety profile. Community accounts are labeled anecdotal, not clinical evidence and are never blended into trial conclusions.

Conflicting or limited evidence is part of the record. The site does not fill gaps with plausible-sounding numbers, unnamed studies, or molecular speculation. Absence of evidence is reported as a limit rather than converted into reassurance.

The Boston and Massachusetts-US frame

Boston is used here as an editorial point of view: a dense research setting where basic biology, translation, clinical trials, and regulation can be seen as one chain. No regional prestige can rescue a weak design, and no compelling mechanism can skip the work of human validation.

The governing regulatory categories are US categories. An approved prescription medicine has been reviewed for a defined product and indication. Tesamorelin’s narrow approval does not become a general fat-loss authorization. Semaglutide’s approved record does not validate unregulated material. A cosmetic role for topical Copper Tripeptide-1 does not establish systemic GHK-Cu therapy. BPC-157 remains unapproved. These distinctions are repeated because they prevent the most common reading errors in peptide coverage.

Corrections and scope

Scientific records change. The editorial desk welcomes precise corrections, newly relevant peer-reviewed work, and regulatory updates through the contact page. A useful note identifies the page, disputed sentence, and source so the claim can be checked in context.

The reference file is intentionally finite. It supports this digest rather than claiming to be a complete systematic review. Inclusion does not imply endorsement, and omission does not establish that no other work exists. The aim is a transparent, bounded reading experience in which every cited claim can be traced and every major uncertainty stays visible.